# Processa Pharmaceuticals (PCSA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PCSA
## Company Profile
- Ticker: PCSA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 2.05 USD
- Market cap: 8030505.16 USD
- Last updated: 2026-09-03
## Business Overview
Processa Pharmaceuticals is a development-stage company focused on improving the safety and efficacy of existing oncology drugs through next-generation formulations and combinations. Its story centers on making known medicines more usable in difficult cancer settings.
## Why The Stock Is Moving

As of Sep 3, 2026, PCSA closed down 2.38% at $2.05. No new same-company headline was identified in the current news window.

## Geographic Base

Processa is headquartered in the United States and listed on NASDAQ. It sits in small-cap biopharmaceutical development.

## Business Model

The business depends on clinical progress, formulation strategy, and the ability to advance a narrow pipeline with limited resources. Investors typically watch proof-of-concept data and partnership or financing activity.

## Landscape Position

Processa occupies a niche oncology-development position within biotech. It is a small-cap story where the commercial value depends on whether modified therapies can truly improve outcomes.

## Future Catalysts

- Processa’s catalysts are its rare-disease and oncology programs, especially any development update that clarifies which assets still matter. The company needs a cleaner clinical path.

## Recent News
- 2026-09-01 11:00 EST — [Processa Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-ee8ad599) — Source: Processa Pharmaceuticals
- 2026-07-29 11:30 EST — [PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS](https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-inc-announces-acquisition-of-vidya-therapeutics-inc-and-589446e2) — Source: Processa Pharmaceuticals
- 2026-01-12 14:15 EST — [Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-to-attend-44th-annual-j-p-morgan-healthcare-conference) — Source: Processa Pharmaceuticals
- 2026-01-05 14:15 EST — [Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study](https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-completes-enrollment-of-20th-patient-for-formal-interim-analysis-in-phase-2-ngc-cap-breast-cancer-study) — Source: Processa Pharmaceuticals
- 2025-12-17 13:00 EST — [Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer](https://biopharmsignal.com/news/PCSA/processa-pharmaceuticals-provides-clinical-update-on-phase-2-study-in-metastatic-breast-cancer) — Source: Processa Pharmaceuticals